인쇄하기
취소
|
At the 2015 9th Drug Price Deliberation Committee, a lot of treatments crossed the health insurance threshold. However, most of them had higher chances to be non-benefited only with cost effectiveness, but pharmaceutical companies accepted prices below the weighted average to acquire the benefit.
According to the Drug Registration Division of the Health Insurance Review & Assessment Service(HI...